Table 3 Summary of Key Variables in MAST Trial Data
Variable | Count | Mean (SD) | Median | Range (Min–Max) | Notes |
|---|---|---|---|---|---|
Patient Characteristics | |||||
Age at Diagnosis (years) | 141 | 62.8 ( ± 8.5) | 63 | 43–85 | — |
NCCN Risk Group | 138 | — | — | — | Very Low (61), Low (53), Intermediate (24) |
Days in Study | 138 | 792.3 ( ± 622.9) | 713.5 | 100–5189 | — |
Overall Progression | 141 | — | — | — | Yes (70), No (71) |
Histological Progression | 141 | — | — | — | Yes (66), No (75) |
Imaging and Biopsy Scores | |||||
Highest PIRADS at Baseline MRI | 138 | 3.10 ( ± 1.48) | 4 | 0–5 | — |
Highest PIRADS at 12 Months | 61 | 2.57 ( ± 1.8) | 3 | 0–5 | — |
Highest PIRADS at 36 Months | 44 | 1.80 ( ± 1.87) | 1.5 | 0–5 | — |
Gleason Grade Progression | |||||
Gleason Grade at Baseline | 43 | 0.44 ( ± 0.50) | 0 | 0–2 | Based on systematic and targeted cores |
Gleason Grade at 12 Months | 43 | 0.58 ( ± 0.50) | 1 | 0–2 | — |
Gleason Grade at 24 Months | 43 | 0.56 ( ± 0.50) | 1 | 0–2 | — |
Gleason Grade at 36 Months | 43 | 0.58 ( ± 0.66) | 1 | 0–3 | Greater variability noted |
